Literature DB >> 23873720

RAS mutations in thyroid cancer.

Gina M Howell1, Steven P Hodak, Linwah Yip.   

Abstract

In recent years, our understanding of the genetic alterations underlying thyroid oncogenesis has greatly expanded. The use of molecular markers, including RAS, in the management of thyroid carcinoma is also increasing. This review summarizes the current literature surrounding RAS and discusses its potential as a diagnostic and prognostic indicator in the management of thyroid cancer.

Entities:  

Keywords:  Molecular markers; RAS; Thyroid cancer; Thyroid nodules

Mesh：

Substances：

Year:  2013        PMID： 23873720      PMCID： PMC3755930          DOI： 10.1634/theoncologist.2013-0072

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  56 in total

1.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

Review 2.  The mitogen-activated protein kinase signal transduction pathway.

Authors:  R J Davis
Journal:  J Biol Chem       Date:  1993-07-15       Impact factor: 5.157

3.  N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression.

Authors:  F Basolo; F Pisaturo; L E Pollina; G Fontanini; R Elisei; E Molinaro; P Iacconi; P Miccoli; F Pacini
Journal:  Thyroid       Date:  2000-01       Impact factor: 6.568

4.  Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology.

Authors:  Silvia Cantara; Marco Capezzone; Stefania Marchisotta; Serena Capuano; Giulia Busonero; Paolo Toti; Andrea Di Santo; Giuseppe Caruso; Anton Ferdinando Carli; Lucia Brilli; Annalisa Montanaro; Furio Pacini
Journal:  J Clin Endocrinol Metab       Date:  2010-02-03       Impact factor: 5.958

5.  Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.

Authors:  Zhaowen Zhu; Manoj Gandhi; Marina N Nikiforova; Andrew H Fischer; Yuri E Nikiforov
Journal:  Am J Clin Pathol       Date:  2003-07       Impact factor: 2.493

Review 6.  Fine-needle aspiration of thyroid nodules: past, present, and future.

Authors:  Zubair W Baloch; Virginia A LiVolsi
Journal:  Endocr Pract       Date:  2004 May-Jun       Impact factor: 3.443

7.  Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance".

Authors:  N Paul Ohori; Marina N Nikiforova; Karen E Schoedel; Shane O LeBeau; Steven P Hodak; Raja R Seethala; Sally E Carty; Jennifer B Ogilvie; Linwah Yip; Yuri E Nikiforov
Journal:  Cancer Cytopathol       Date:  2010-02-25       Impact factor: 5.284

Review 8.  BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

Authors:  Mingzhao Xing
Journal:  Endocr Rev       Date:  2007-10-16       Impact factor: 19.871

9.  Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours.

Authors:  Ana Banito; António E Pinto; Carla Espadinha; Ana Rita Marques; Valeriano Leite
Journal:  Clin Endocrinol (Oxf)       Date:  2007-07-25       Impact factor: 3.478

10.  Significance of lymph node metastasis in differentiated thyroid cancer.

Authors:  J Harwood; O H Clark; J E Dunphy
Journal:  Am J Surg       Date:  1978-07       Impact factor: 2.565
View more
  53 in total

1.  [Fine-needle aspiration (FNA) of the thyroid gland : Analysis of discrepancies between cytological and histological diagnoses].

Authors:  P Dalquen; B Rashed; A Hinsch; R Issa; T Clauditz; A Luebke; J Lüttges; W Saeger; K H Bohuslavizki
Journal:  Pathologe       Date:  2016-09       Impact factor: 1.011

2.  Epstein-Barr virus induces morphological and molecular changes in thyroid neoplastic cells.

Authors:  Jacqueline Fátima Martins Almeida; José Luiz Proenca-Modena; Natássia Elena Bufalo; Karina Colombera Peres; Elisângela de Souza Teixeira; Larissa Teodoro; Raíssa Marques Beck; Ana Paula Moraes; Alfio José Tincani; Clarice Weis Arns; Laura Sterian Ward
Journal:  Endocrine       Date:  2020-03-12       Impact factor: 3.633

Review 3.  Novel approaches in anaplastic thyroid cancer therapy.

Authors:  Kun-Tai Hsu; Xiao-Min Yu; Anjon W Audhya; Juan C Jaume; Ricardo V Lloyd; Shigeki Miyamoto; Tomas A Prolla; Herbert Chen
Journal:  Oncologist       Date:  2014-09-26

Review 4.  Values of molecular markers in the differential diagnosis of thyroid abnormalities.

Authors:  T M P B Tennakoon; M Rushdhi; A D C U Ranasinghe; R S Dassanayake
Journal:  J Cancer Res Clin Oncol       Date:  2016-12-22       Impact factor: 4.553

5.  A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.

Authors:  Razelle Kurzrock; Douglas W Ball; Steven I Sherman; Nilofer S Azad; Marianna L Zahurak; Barry D Nelkin; Vivek Subbiah; Shabina Ahmed; Ashley O'Connor; Enusha Karunsena; Rose M Parkinson; Justin A Bishop; Yoonji Ha; Rajni Sharma; Christopher D Gocke; Ralph Zinner; Michelle A Rudek
Journal:  Clin Cancer Res       Date:  2019-06-11       Impact factor: 12.531

Review 6.  Clinical application of molecular testing of fine-needle aspiration specimens in thyroid nodules.

Authors:  Linwah Yip; Robert L Ferris
Journal:  Otolaryngol Clin North Am       Date:  2014-06-12       Impact factor: 3.346

7.  Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.

Authors:  Tali Ofir Dovrat; Ethan Sokol; Garrett Frampton; Eliya Shachar; Sharon Pelles; Ravit Geva; Ido Wolf
Journal:  Cancer Biol Ther       Date:  2018-07-23       Impact factor: 4.742

8.  Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study.

Authors:  Christelle de la Fouchardiere; Nadia Oussaid; Olfa Derbel; Myriam Decaussin-Petrucci; Marie-Eve Fondrevelle; Qing Wang; Pierre-Paul Bringuier; Claire Bournaud-Salinas; Jean-Louis Peix; Jean-Christophe Lifante; Anne-Laure Giraudet; Jonathan Lopez; Françoise Borson-Chazot
Journal:  Target Oncol       Date:  2016-02       Impact factor: 4.493

Review 9.  Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.

Authors:  Sujata Narayanan; A Dimitrios Colevas
Journal:  Curr Treat Options Oncol       Date:  2016-06

10.  Clinical, Sonographic, and Pathological Characteristics of RAS-Positive Versus BRAF-Positive Thyroid Carcinoma.

Authors:  Sujay Kakarmath; Howard T Heller; Caroline A Alexander; Edmund S Cibas; Jeffrey F Krane; Justine A Barletta; Neal I Lindeman; Mary C Frates; Carol B Benson; Atul A Gawande; Nancy L Cho; Matthew Nehs; Francis D Moore; Ellen Marqusee; Mathew I Kim; P Reed Larsen; Norra Kwong; Trevor E Angell; Erik K Alexander
Journal:  J Clin Endocrinol Metab       Date:  2016-09-30       Impact factor: 5.958
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.